186 related articles for article (PubMed ID: 21998400)
1. Effect of rosiglitazone on bone quality in a rat model of insulin resistance and osteoporosis.
Sardone LD; Renlund R; Willett TL; Fantus IG; Grynpas MD
Diabetes; 2011 Dec; 60(12):3271-8. PubMed ID: 21998400
[TBL] [Abstract][Full Text] [Related]
2. The effect of rosiglitazone on bone mass and fragility is reversible and can be attenuated with alendronate.
Kumar S; Hoffman SJ; Samadfam R; Mansell P; Jolette J; Smith SY; Guldberg RE; Fitzpatrick LA
J Bone Miner Res; 2013 Jul; 28(7):1653-65. PubMed ID: 23456892
[TBL] [Abstract][Full Text] [Related]
3. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus.
Bilezikian JP; Josse RG; Eastell R; Lewiecki EM; Miller CG; Wooddell M; Northcutt AR; Kravitz BG; Paul G; Cobitz AR; Nino AJ; Fitzpatrick LA
J Clin Endocrinol Metab; 2013 Apr; 98(4):1519-28. PubMed ID: 23450056
[TBL] [Abstract][Full Text] [Related]
4. Alendronate retards the progression of lumbar intervertebral disc degeneration in ovariectomized rats.
Luo Y; Zhang L; Wang WY; Hu QF; Song HP; Su YL; Zhang YZ
Bone; 2013 Aug; 55(2):439-48. PubMed ID: 23500174
[TBL] [Abstract][Full Text] [Related]
5. Effects of combination treatment with alendronate and vitamin K(2) on bone mineral density and strength in ovariectomized mice.
Sasaki H; Miyakoshi N; Kasukawa Y; Maekawa S; Noguchi H; Kamo K; Shimada Y
J Bone Miner Metab; 2010 Jul; 28(4):403-9. PubMed ID: 20101424
[TBL] [Abstract][Full Text] [Related]
6. Differential maintenance of cortical and cancellous bone strength following discontinuation of bone-active agents.
Shahnazari M; Yao W; Wang B; Panganiban B; Ritchie RO; Hagar Y; Lane NE
J Bone Miner Res; 2011 Mar; 26(3):569-81. PubMed ID: 20839286
[TBL] [Abstract][Full Text] [Related]
7. Effects of denosumab, alendronate, or denosumab following alendronate on bone turnover, calcium homeostasis, bone mass and bone strength in ovariectomized cynomolgus monkeys.
Kostenuik PJ; Smith SY; Samadfam R; Jolette J; Zhou L; Ominsky MS
J Bone Miner Res; 2015 Apr; 30(4):657-69. PubMed ID: 25369992
[TBL] [Abstract][Full Text] [Related]
8. A rat osteoporotic spine model for the evaluation of bioresorbable bone cements.
Wang ML; Massie J; Perry A; Garfin SR; Kim CW
Spine J; 2007; 7(4):466-74. PubMed ID: 17630145
[TBL] [Abstract][Full Text] [Related]
9. Can the alendronate dosage be altered when combined with high-frequency loading in osteoporosis treatment?
Correa CB; Camargos GV; Chatterjee M; Mesquita MF; Del Bel Cury AA; Naert I; Duyck J; Vandamme K
Osteoporos Int; 2017 Apr; 28(4):1287-1293. PubMed ID: 27921147
[TBL] [Abstract][Full Text] [Related]
10. Alendronate (ALN) combined with osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats.
Wang Y; Huang P; Tang PF; Chan KM; Li G
J Orthop Surg Res; 2011 Jul; 6():34. PubMed ID: 21752290
[TBL] [Abstract][Full Text] [Related]
11. Single and combined effect of high-frequency loading and bisphosphonate treatment on the bone micro-architecture of ovariectomized rats.
Hatori K; Camargos GV; Chatterjee M; Faot F; Sasaki K; Duyck J; Vandamme K
Osteoporos Int; 2015 Jan; 26(1):303-13. PubMed ID: 25236876
[TBL] [Abstract][Full Text] [Related]
12. Effects of combined treatment with eldecalcitol and alendronate on bone mass, mechanical properties, and bone histomorphometry in ovariectomized rats: a comparison with alfacalcidol and alendronate.
Sugimoto M; Futaki N; Harada M; Kaku S
Bone; 2013 Jan; 52(1):181-8. PubMed ID: 23041510
[TBL] [Abstract][Full Text] [Related]
13. Effects of alendronate on lumbar intervertebral disc degeneration with bone loss in ovariectomized rats.
Song H; Luo Y; Wang W; Li S; Yang K; Dai M; Shen Y; Zhang Y; Zhang L
Spine J; 2017 Jul; 17(7):995-1003. PubMed ID: 28288923
[TBL] [Abstract][Full Text] [Related]
14. Mechanical competence of ovariectomy-induced compromised bone after single or combined treatment with high-frequency loading and bisphosphonates.
Camargos GV; Bhattacharya P; van Lenthe GH; Del Bel Cury AA; Naert I; Duyck J; Vandamme K
Sci Rep; 2015 Jun; 5():10795. PubMed ID: 26027958
[TBL] [Abstract][Full Text] [Related]
15. In vivo effects of two novel ALN-EP4a conjugate drugs on bone in the ovariectomized rat model for reversing postmenopausal bone loss.
Hu S; Liu CC; Chen G; Willett T; Young RN; Grynpas MD
Osteoporos Int; 2016 Feb; 27(2):797-808. PubMed ID: 26272313
[TBL] [Abstract][Full Text] [Related]
16. Combination treatment with pioglitazone and fenofibrate attenuates pioglitazone-mediated acceleration of bone loss in ovariectomized rats.
Samadfam R; Awori M; Bénardeau A; Bauss F; Sebokova E; Wright M; Smith SY
J Endocrinol; 2012 Feb; 212(2):179-86. PubMed ID: 22062085
[TBL] [Abstract][Full Text] [Related]
17. Comparison of calcitonin, alendronate and fluorophosphate effects on ovariectomized rat bone.
Giavaresi G; Fini M; Gnudi S; Aldini NN; Rocca M; Carpi A; Giardino R
Biomed Pharmacother; 2001 Sep; 55(7):397-403. PubMed ID: 11669503
[TBL] [Abstract][Full Text] [Related]
18. Odanacatib, effects of 16-month treatment and discontinuation of therapy on bone mass, turnover and strength in the ovariectomized rabbit model of osteopenia.
Duong LT; Crawford R; Scott K; Winkelmann CT; Wu G; Szczerba P; Gentile MA
Bone; 2016 Dec; 93():86-96. PubMed ID: 27639811
[TBL] [Abstract][Full Text] [Related]
19. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats.
Li X; Ominsky MS; Warmington KS; Niu QT; Asuncion FJ; Barrero M; Dwyer D; Grisanti M; Stolina M; Kostenuik PJ; Simonet WS; Paszty C; Ke HZ
Endocrinology; 2011 Sep; 152(9):3312-22. PubMed ID: 21733832
[TBL] [Abstract][Full Text] [Related]
20. Prolonged treatments with antiresorptive agents and PTH have different effects on bone strength and the degree of mineralization in old estrogen-deficient osteoporotic rats.
Cheng Z; Yao W; Zimmermann EA; Busse C; Ritchie RO; Lane NE
J Bone Miner Res; 2009 Feb; 24(2):209-20. PubMed ID: 18847326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
